Submit
Search
Submit
Menu

  • Information

  • References

  • Contents

  • [1]J. S. Ross: Cancer biomarkers, companion diagnostics and personalized oncology. Biomark Med, 5(3), 277-9 (2011)

  • [2]R. Conti, D. L. Veenstra, K. Armstrong, L. J. Lesko and S. D. Grosse: Personalized medicine and genomics: challenges and opportunities in assessing effectiveness, cost-effectiveness, and future research priorities. Med Decis Making, 30(3), 328-40 (2010)

  • [3]A. Dimou, K. Syrigos and M. W. Saif: Novel modalities in the treatment of patients with KRAS-mutated colorectal cancer. Anticancer Drugs, 22(5), 384-91 (2011)

  • [4]M. Holderfield, M. M. Deuker, F. McCormick and M. McMahon: Targeting RAF kinases for cancer therapy: BRAF-mutated melanoma and beyond. Nat Rev Cancer, 14(7), 455-67 (2014)

  • [5]A. Varond: Trends in Personalized Medicine. Regulatory Focus, 1-5 (2013)

  • [6]H. F. Yancy, J. A. Mason, S. Peters, C. E. Thompson, 3rd, G. K. Littleton, M. Jett and A. A. Day: Metastatic progression and gene expression between breast cancer cell lines from African American and Caucasian women. J Carcinog, 6, 8 (2007)

  • [7]M. Schootman, D. B. Jeffe, W. E. Gillanders and R. Aft: Racial disparities in the development of breast cancer metastases among older women: a multilevel study. Cancer, 115(4), 731-40 (2009)

  • [8]S. Wang, T. H. Dorsey, A. Terunuma, R. A. Kittles, S. Ambs and B. Kwabi-Addo: Relationship between tumor DNA methylation status and patient characteristics in African-American and European-American women with breast cancer. PLoS One, 7(5), e37928 (2012)

  • [9]D. N. Martin, B. J. Boersma, M. Yi, M. Reimers, T. M. Howe, H. G. Yfantis, Y. C. Tsai, E. H. Williams, D. H. Lee, R. M. Stephens, A. M. Weissman and S. Ambs: Differences in the tumor microenvironment between African-American and European-American breast cancer patients. PLoS One, 4(2), e4531 (2009)

  • [10]J. A. Canter, A. R. Kallianpur, F. F. Parl and R. C. Millikan: Mitochondrial DNA G10398A polymorphism and invasive breast cancer in African-American women. Cancer Res, 65(17), 8028-33 (2005)

  • [11]V. T. DeVita, Jr. and E. Chu: A history of cancer chemotherapy. Cancer Res, 68(21), 8643-53 (2008)

  • [12]S. H. Cho, J. Jeon and S. I. Kim: Personalized medicine in breast cancer: a systematic review. J Breast Cancer, 15(3), 265-72 (2012)

  • [13]D. Olsen and J. T. Jorgensen: Companion diagnostics for targeted cancer drugs - clinical and regulatory aspects. Front Oncol, 4, 105 (2014)

  • [14]H. Winther and J. Jørgensen: Drug-diagnostic co-development in cancer. Pharmaceutical Medicine 24(6), 363-375 (2010)

  • [15]J. C. Barrett, M. M. Frigault, S. Hollingsworth, G. A. Miller and V. Modur: Are companion diagnostics useful? Clin Chem, 59(1), 198-201 (2013)

  • [16]D. J. Slamon, B. Leyland-Jones, S. Shak, H. Fuchs, V. Paton, A. Bajamonde, T. Fleming, W. Eiermann, J. Wolter, M. Pegram, J. Baselga and L. Norton: Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2. N Engl J Med, 344(11), 783-92 (2001)

  • [17]C. Pedersen and J. Jørgensen: Companion Diagnostics

  • [18]S. M. Swain, J. Baselga, S. B. Kim, J. Ro, V. Semiglazov, M. Campone, E. Ciruelos, J. M. Ferrero, A. Schneeweiss, S. Heeson, E. Clark, G. Ross, M. C. Benyunes, J. Cortes and C. S. Group: Pertuzumab, trastuzumab, and docetaxel in HER2-positive metastatic breast cancer. N Engl J Med, 372(8), 724-34 (2015)

  • [19]S. M. Swain, S. B. Kim, J. Cortes, J. Ro, V. Semiglazov, M. Campone, E. Ciruelos, J. M. Ferrero, A. Schneeweiss, A. Knott, E. Clark, G. Ross, M. C. Benyunes and J. Baselga: Pertuzumab, trastuzumab, and docetaxel for HER2-positive metastatic breast cancer (CLEOPATRA study): overall survival results from a randomised, double-blind, placebo-controlled, phase 3 study. Lancet Oncol, 14(6), 461-71 (2013)

  • [20]C. E. Geyer, J. Forster, D. Lindquist, S. Chan, C. G. Romieu, T. Pienkowski, A. Jagiello-Gruszfeld, J. Crown, A. Chan, B. Kaufman, D. Skarlos, M. Campone, N. Davidson, M. Berger, C. Oliva, S. D. Rubin, S. Stein and D. Cameron: Lapatinib plus capecitabine for HER2-positive advanced breast cancer. N Engl J Med, 355(26), 2733-43 (2006)

  • [21]Z. Guan, B. Xu, M. L. DeSilvio, Z. Shen, W. Arpornwirat, Z. Tong, V. Lorvidhaya, Z. Jiang, J. Yang, A. Makhson, W. L. Leung, M. W. Russo, B. Newstat, L. Wang, G. Chen, C. Oliva and H. Gomez: Randomized trial of lapatinib versus placebo added to paclitaxel in the treatment of human epidermal growth factor receptor 2-overexpressing metastatic breast cancer. J Clin Oncol, 31(16), 1947-53 (2013)

  • [22]J. T. Jorgensen: A challenging drug development process in the era of personalized medicine. Drug Discov Today, 16(19-20), 891-7 (2011)

  • [23]H. J. Lerner, P. R. Band, L. Israel and B. S. Leung: Phase II study of tamoxifen: report of 74 patients with stage IV breast cancer. Cancer Treat Rep, 60(10), 1431-5 (1976)

  • [24]R. Munagala, F. Aqil and R. C. Gupta: Promising molecular targeted therapies in breast cancer. Indian J Pharmacol, 43(3), 236-45 (2011)

  • [25]R. K. Jain, D. G. Duda, J. W. Clark and J. S. Loeffler: Lessons from phase III clinical trials on anti-VEGF therapy for cancer. Nat Clin Pract Oncol, 3(1), 24-40 (2006)

  • [26]K. Miller, M. Wang, J. Gralow, M. Dickler, M. Cobleigh, E. A. Perez, T. Shenkier, D. Cella and N. E. Davidson: Paclitaxel plus bevacizumab versus paclitaxel alone for metastatic breast cancer. N Engl J Med, 357(26), 2666-76 (2007)

  • [27]J. Y. Hsu and H. A. Wakelee: Monoclonal antibodies targeting vascular endothelial growth factor: current status and future challenges in cancer therapy. Bio Drugs, 23(5), 289-304 (2009)

  • [28]T. Keenan, B. Moy, E. A. Mroz, K. Ross, A. Niemierko, J. W. Rocco, S. Isakoff, L. W. Ellisen and A. Bardia: Comparison of the Genomic Landscape Between Primary Breast Cancer in African American Versus White Women and the Association of Racial Differences With Tumor Recurrence. J Clin Oncol, 33(31), 3621-7 (2015)

  • [29]J. E. Churpek, T. Walsh, Y. Zheng, Z. Moton, A. M. Thornton, M. K. Lee, S. Casadei, A. Watts, B. Neistadt, M. M. Churpek, D. Huo, C. Zvosec, F. Liu, Q. Niu, R. Marquez, J. Zhang, J. Fackenthal, M. C. King and O. I. Olopade: Inherited predisposition to breast cancer among African American women. Breast Cancer Res Treat, 149(1), 31-9 (2015)

  • [30]C. Anders and L. A. Carey: Understanding and treating triple-negative breast cancer. Oncology (Williston Park), 22(11), 1233-9; discussion 1239-40, 1243 (2008)

  • [31]B. G. Haffty, Q. Yang, M. Reiss, T. Kearney, S. A. Higgins, J. Weidhaas, L. Harris, W. Hait and D. Toppmeyer: Locoregional relapse and distant metastasis in conservatively managed triple negative early-stage breast cancer. J Clin Oncol, 24(36), 5652-7 (2006)

  • [32]C. K. Anders, E. P. Winer, J. M. Ford, R. Dent, D. P. Silver, G. W. Sledge and L. A. Carey: Poly(ADP-Ribose) polymerase inhibition: “targeted” therapy for triple-negative breast cancer. Clin Cancer Res, 16(19), 4702-10 (2010)

  • [33]P. McGlynn and R. G. Lloyd: Recombinational repair and restart of damaged replication forks. Nat Rev Mol Cell Biol, 3(11), 859-70 (2002)

  • [34]R. Buisson, A. M. Dion-Cote, Y. Coulombe, H. Launay, H. Cai, A. Z. Stasiak, A. Stasiak, B. Xia and J. Y. Masson: Cooperation of breast cancer proteins PALB2 and piccolo BRCA2 in stimulating homologous recombination. Nat Struct Mol Biol, 17(10), 1247-54 (2010)

  • [35]H. Liang and A. Tan: PARP Inhibitors. Curr Breast Cancer Rep, 3, 44-54 (2011)

  • [36]B. A. Jones, S. V. Kasl, C. L. Howe, M. Lachman, R. Dubrow, M. M. Curnen, H. Soler-Vila, A. Beeghly, F. Duan and P. Owens: African-American/White differences in breast carcinoma: p53 alterations and other tumor characteristics. Cancer, 101(6), 1293-301 (2004)

  • [37]G. J. Morris, S. Naidu, A. K. Topham, F. Guiles, Y. Xu, P. McCue, G. F. Schwartz, P. K. Park, A. L. Rosenberg, K. Brill and E. P. Mitchell: Differences in breast carcinoma characteristics in newly diagnosed African-American and Caucasian patients: a single-institution compilation compared with the National Cancer Institute’s Surveillance, Epidemiology, and End Results database. Cancer, 110(4), 876-84 (2007)

  • [38]E. Tan and C. Cheok: Bringing p53 into the Clinic; Cancer Sci The, 6(9), 363-369 (2014)

  • [39]J. A. Mason, H. F. Yancy, K. Lashley, M. Jett and A. A. Day: Comparative study of matrix metalloproteinase expression between African American and Caucasian Women. J Carcinog, 3(1), 15 (2004)

  • [40]C. Erlichman, A. A. Adjei, S. R. Alberts, J. A. Sloan, R. M. Goldberg, H. C. Pitot, J. Rubin, P. J. Atherton, G. G. Klee and R. Humphrey: Phase I study of the matrix metalloproteinase inhibitor, BAY 12-9566. Ann Oncol, 12(3), 389-95 (2001)

  • [41]J. Baselga, P. Gomez, R. Greil, S. Braga, M. A. Climent, A. M. Wardley, B. Kaufman, S. M. Stemmer, A. Pego, A. Chan, J. C. Goeminne, M. P. Graas, M. J. Kennedy, E. M. Ciruelos Gil, A. Schneeweiss, A. Zubel, J. Groos, H. Melezinkova and A. Awada: Randomized phase II study of the anti-epidermal growth factor receptor monoclonal antibody cetuximab with cisplatin versus cisplatin alone in patients with metastatic triple-negative breast cancer. J Clin Oncol, 31(20), 2586-92 (2013)

  • [42]S. Rummel, C. E. Penatzer, C. D. Shriver and R. E. Ellsworth: PSPHL and breast cancer in African American women: causative gene or population stratification? BMC Genet, 15, 38 (2014)

  • [43]L. Field, B. Love, B. Deyarmin, A. Hooke, D. Shriver and E. Ellsworth: Identification of differentially expressed genes in breast tumors from African American compared with Caucasian women. Cancer, 118(5), 1334-1344 (2012)

  • [44]D. N. Danforth, Jr.: Disparities in breast cancer outcomes between Caucasian and African American women: a model for describing the relationship of biological and nonbiological factors. Breast Cancer Res, 15(3), 208 (2013)

  • [45]C. Guillemette, R. C. Millikan, B. Newman and D. E. Housman: Genetic polymorphisms in uridine diphospho-glucuronosyltransferase 1A1 and association with breast cancer among African Americans. Cancer Res, 60(4), 950-6(2000) (doi not found)

  • [46]W. E. Evans and M. V. Relling: Pharmacogenomics: translating functional genomics into rational therapeutics. Science, 286(5439), 487-91 (1999)

  • [47]L. W. Loo, Y. Wang, E. M. Flynn, M. J. Lund, E. J. Bowles, D. S. Buist, J. M. Liff, E. W. Flagg, R. J. Coates, J. W. Eley, L. Hsu and P. L. Porter: Genome-wide copy number alterations in subtypes of invasive breast cancers in young white and African American women. Breast Cancer Res Treat, 127(1), 297-308 (2011)

  • [48]S. Cleator, W. Heller and R. C. Coombes: Triple-negative breast cancer: therapeutic options. Lancet Oncol, 8(3), 235-44 (2007)

  • [49]A. Bergamaschi, Y. H. Kim, P. Wang, T. Sorlie, T. Hernandez-Boussard, P. E. Lonning, R. Tibshirani, A. L. Borresen-Dale and J. R. Pollack: Distinct patterns of DNA copy number alteration are associated with different clinicopathological features and gene-expression subtypes of breast cancer. Genes Chromosomes Cancer, 45(11), 1033-40 (2006)

  • [50]J. Mehrotra, M. M. Ganpat, Y. Kanaan, M. J. Fackler, M. McVeigh, J. Lahti-Domenici, K. Polyak, P. Argani, T. Naab, E. Garrett, G. Parmigiani, C. Broome and S. Sukumar: Estrogen receptor/progesterone receptor-negative breast cancers of young African-American women have a higher frequency of methylation of multiple genes than those of Caucasian women. Clin Cancer Res, 10(6), 2052-7 (2004)

  • [51]S. S. Palii, B. O. Van Emburgh, U. T. Sankpal, K. D. Brown and K. D. Robertson: DNA methylation inhibitor 5-Aza-2’-deoxycytidine induces reversible genome-wide DNA damage that is distinctly influenced by DNA methyltransferases 1 and 3B. Mol Cell Biol, 28(2), 752-71 (2008)

  • [52]H. Heyn and M. Esteller: DNA methylation profiling in the clinic: applications and challenges. Nat Rev Genet, 13(10), 679-92 (2012)

  • [53]A. B. D’Assoro, W. L. Lingle and J. L. Salisbury: Centrosome amplification and the development of cancer. Oncogene, 21(40), 6146-53 (2002)

  • [54]W. L. Lingle, S. L. Barrett, V. C. Negron, A. B. D’Assoro, K. Boeneman, W. Liu, C. M. Whitehead, C. Reynolds and J. L. Salisbury: Centrosome amplification drives chromosomal instability in breast tumor development. Proc Natl Acad Sci U S A, 99(4), 1978-83 (2002)

  • [55]V. Pannu, K. Mittal, G. Cantuaria, M. D. Reid, X. Li, S. Donthamsetty, M. McBride, S. Klimov, R. Osan, M. V. Gupta, P. C. Rida and R. Aneja: Rampant centrosome amplification underlies more aggressive disease course of triple negative breast cancers. Oncotarget, 6(12), 10487-97 (2015)

  • [56]P. Boyle: Triple-negative breast cancer: epidemiological considerations and recommendations. Ann Oncol, 23 Suppl 6, vi7-12 (2012)

  • [57]B. R. Brinkley: Managing the centrosome numbers game: from chaos to stability in cancer cell division. Trends Cell Biol, 11(1), 18-21 (2001)

  • [58]N. J. Quintyne, J. E. Reing, D. R. Hoffelder, S. M. Gollin and W. S. Saunders: Spindle multipolarity is prevented by centrosomal clustering. Science, 307(5706), 127-9 (2005)

  • [59]A. Ogden, A. Cheng, P. C. Rida, V. Pannu, R. Osan, R. Clewley and R. Aneja: Quantitative multi-parametric evaluation of centrosome declustering drugs: centrosome amplification, mitotic phenotype, cell cycle and death. Cell Death Dis, 5, e1204 (2014)

  • [60]J. Wu, K. Mikule, W. Wang, N. Su, P. Petteruti, F. Gharahdaghi, E. Code, X. Zhu, K. Jacques, Z. Lai, B. Yang, M. L. Lamb, C. Chuaqui, N. Keen and H. Chen: Discovery and mechanistic study of a small molecule inhibitor for motor protein KIFC1. ACS Chem Biol, 8(10), 2201-8 (2013)

  • [61]C. A. Watts, F. M. Richards, A. Bender, P. J. Bond, O. Korb, O. Kern, M. Riddick, P. Owen, R. M. Myers, J. Raff, F. Gergely, D. I. Jodrell and S. V. Ley: Design, synthesis, and biological evaluation of an allosteric inhibitor of HSET that targets cancer cells with supernumerary centrosomes. Chem Biol, 20(11), 1399-410 (2013)

  • [62]Z. Tezak, M. Zivana, M. Kondratovich and E. Mansfield: US FDA and personalized medicine: in vitro diagnostic regulatory perspective. Personalized Medicine, 7(5), 517-530 (2010)

  • [63]R. T. McCormack, J. Armstrong and D. Leonard: Codevelopment of genome-based therapeutics and companion diagnostics: insights from an Institute of Medicine roundtable. JAMA, 311(14), 1395-6 (2014)

  • [64]M. A. Hamburg and F. S. Collins: The path to personalized medicine. N Engl J Med, 363(4), 301-4 (2010)

  • [65]E. A. Mansfield: FDA perspective on companion diagnostics: an evolving paradigm. Clin Cancer Res, 20(6), 1453-7 (2014)

  • [66]J. D. Khoury and D. V. Catenacci: Next-generation companion diagnostics: promises, challenges, and solutions. Arch Pathol Lab Med, 139(1), 11-3 (2015)

  • [67]S. Pant, R. Weiner and M. J. Marton: Navigating the rapids: the development of regulated next-generation sequencing-based clinical trial assays and companion diagnostics. Front Oncol, 4, 78 (2014)

  • [68]R. A. Montagna: Meeting the technical challenges of personalized medicine and companion diagnostics. MLO Med Lab Obs, 44(1), 16, 18, 20 passim (2012)

  • [69]D. R. Parkinson, B. E. Johnson and G. W. Sledge: Making personalized cancer medicine a reality: challenges and opportunities in the development of biomarkers and companion diagnostics. Clin Cancer Res, 18(3), 619-24 (2012)

  • [70]M. Moore, B. Deepti and P. Cotter: Challenges in the codevelopment of companion diagnostics.” Personalized Medicine, 9(5) 485-496 (2012)

  • [71]J. C. Davis, L. Furstenthal, A. A. Desai, T. Norris, S. Sutaria, E. Fleming and P. Ma: The microeconomics of personalized medicine: today’s challenge and tomorrow’s promise. Nat Rev Drug Discov, 8(4), 279-86 (2009)

Article Metrics

  • Information

  • Download

  • Contents

Frontiers in Bioscience-Landmark (FBL) is published by IMR Press from Volume 26 Issue 5 (2021). Previous articles were published by another publisher on a subscription basis, and they are hosted by IMR Press on imrpress.com as a courtesy and upon agreement with Frontiers in Bioscience.

1 Jan 2017Review

Targeted drugs and diagnostic assays: Companions in the race to combat ethnic disparity

Nikita Wright 1, Padmashree Rida 1,2, Uma Krishnamurti 3, Xiaoxian Li 3, Ritu Aneja 1,*
Affiliations
Article Info

1 Department of Biology, Georgia State University, Atlanta, GA 30303, USA

2 Novazoi Theranostics, Plano, TX 75025, USA

3 Department of Pathology and Laboratory Medicine, Emory University Hospital, Atlanta, GA 30322, USA

Abstract

African Americans (AAs) are more likely than European Americans to develop aggressive breast cancer subtypes, and have higher recurrence and mortality rates; this results in a stark breast-cancer related ethnic disparity in clinical outcomes. In this era of personalized oncology, companion diagnostics (CDx) are transforming the cancer treatment narrative slowly but steadily, by enabling the use of safety and/or efficacy biomarkers to stratify patient populations, and thus ensuring more effective deployment of targeted therapeutics. This parallel co-development of drugs and in vitro diagnostic assays is turning out to be the cornerstone of individualized cancer treatment. In this review, we assert that development of drugs and CDx targeted towards molecular and centrosomal aberrations that occur more frequently in AAs could yield next generation precision medicine tools better informed and inspired by, and more finely attuned to the unique tumor biology of AAs. By understanding more deeply ancestry-associated differences among breast tumors of different ethnicities, and gearing our drug and CDx development efforts to target these distinctions, we might be able to significantly alleviate racial health disparity.

Keywords

  • Targeted Therapy
  • Companion Diagnostics
  • Personalized Medicine
  • Racial Disparity
  • Breast Cancer
  • Biomarker
  • Review

References